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Background: Cyclic adenosine 5’-diphosphate ribose (cADPR), a naturally 
occurring metabolite of nicotinamide adenine dinucleotide (NAD+), mobilizes 
Ca2+ from non-mitochondrial stores in a variety of mammalian and invertebrate 
tissues. It has been shown that cADPR activates ryanodine-sensitive Ca*+-release 
channels, working independently of inositol 1,4,5-trisphosphate (IP,) to mobilize 
intracellular Ca*+ stores. In some systems, cADPR has been shown to be more 
potent than IP,. The chemo-enzymatic synthesis of structurally modified 
analogues of cADPR can provide pharmacological tools for probing this new 
Ca*+-signaling pathway. In this work, we describe the synthesis and evaluation of 
a structural mimic of cADPR with different Ca*+-releasing properties. 
Results: 7-Deaza cyclic adenosine 5’-diphosphate ribose (7-deaza cADPR), a 
novel cADPR analogue modified in the purine ring, was synthesized and its 
ability to release Ca*+ from non-mitochondrial pools in homogenates made from 
sea urchin eggs was investigated. 7-Deaza cADPR was more effective in 
releasing Ca*+ than cADPR, but it only released approximately 66% of the Ca*+ 
released by a maximal concentration of cADPR. It was also more resistant to 
hydrolysis than cADPR. If we administered increasing concentrations of 7-deaza 
cADPR at the same time as a maximal concentration of cADPR, the induction of 
Ca*+ release by cADPR was antagonized. 
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Conclusions: 7-Deaza cADPR has a Ca*+-release profile consistent with that of 
a partial agonist, and it is the first reported example of such a compound to act 
at the cADPR receptor. The imidazole ring of cADPR is clearly important in 
stimulating the Ca*+-release machinery, and the present results demonstrate that 
structural modification of a site other than position 8 of the purine ring can affect 
the efficacy of Ca*+ release. 7-Deaza cADPR represents a significant step 
forwards in designing modulators of the cADPR signaling pathway. 
Introduction 
Cyclic adenosine 5’-diphosphate ribose (cADPR, 1, Fig. 1) 
is a candidate second messenger that mobilizes Caa+ from 
non-mitochondrial stores in a variety of mammalian and 
invertebrate tissues [l--3]. The metabolic steps known to 
synthesize [4] and degrade [S] cADPR are understood and 
its N1-ribosylated cyclic structure has been confirmed by 
X-ray crystallography [6]. The compound is of particular 
interest because it is known to be more effective than, and 
to work independently of, inositol 1,4,5trisphosphate in 
mobilizing internal stores of Ca*+ in sea urchin eggs. It was 
in sea urchin eggs that its Ca2+ -releasing activity was first 
discovered [7]. Enzymes that synthesize and degrade 
cADPR are widely expressed in mammalian tissues, and 
in human lymphocytes, CD38 - a surface antigen - acts 
as a bifunctional enzyme for both synthesizing and 
degrading cADPR [8,9]. 
The exact mechanism by which cADPR mobilizes Ca2+ is 
still unknown. Initial evidence led to the proposal that, 
cADPR modulates the ryanodine receptor and because it 
sensitizes a ryanodine-sensitive Caa+-release mechanism 
to activation by divalent cations [lo], it is an endogenous 
modulator of calcium-induced calcium release (CICR). In 
addition, it has recently been discovered that the binding 
of calmodulin to the ryanodine receptor can confer 
increased sensitivity on the cADPR-modulated CICR 
mechanism [ll]. But cADPR may also serve as a potential 
second messenger, and such an action has been proposed 
to be involved in insulin release [3]. This idea is sup- 
ported by the ability of nitric oxide (NO) and 3’,5’-cyclic 
guanosine monophosphate (cGMP) to mobilize intracellu- 
lar Caa+ release in sea urchin eggs by stimulating cADPR 
synthesis [l&13]. It has also been reported that the chole- 
cystokinin octdpeptide can augment the synthesis of 
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Figure 1 
The structures of cADPR (1) 7-deaza cADPR 
(4) and 8-amino cADPR (5). 
HO OH HO OH 
X=N, cADPR (1) 8-amino cADPR (5) 
X=CH, 7-deaza cADPR (4) 
cADPR in mammalian intestinal longitundinal smooth 
muscle in a concentration-dependent manner [14]. A 
schematic representation of the Ca2+-signaling pathways 
in sea urchin eggs is shown in Figure 2. 
The importance of structurally modified analogues of 
cADPR as pharmacological tools for the further investiga- 
tion of its biological properties is readily apparent. In order 
to produce such compounds most effectively we, like others 
[15], have relied upon a chemo-enzymatic approach to 
prepare cADPR itself and to generate structural diversity 
(see Fig. 3 for the synthesis of 7-deaza cADPR) [16]. 
A key requirement of this approach in the synthesis of 
structural analogues of cADPR is the loose substrate-speci- 
ficity of the enzyme which cyclizes P-nicotinamide adenine 
dinucleotide (P-NAD+). Nucleosides and their analogues 
are thus selectively phosphorylated and the resultant 
nucleotides (e.g. 2, Fig. 3) are chemically coupled, yielding 
either P-NAD+ or an appropriate analogue (e.g. 3, Fig. 3). 
The product is cyclized enzymatically by Aplysia ADP- 
ribosyl cyclase in a third step to yield either natural cADPR 
(1, Fig. 1) or a modified cADPR analogue, respectively (e.g. 
4 and 5, Fig. 1). As well as being used for the synthesis of a 
number of sugar and purine modified analogues, this 
approach has also led to the identification of the first poorly 
hydrolyzed analogue of cADPR, cyclic aristeromycin 
5’-diphosphate ribose (cArisDPR) [ 171. 
Using synthetic modifications, we have identified a 
number of cADPR-like agonists [16]. Previously, Samino 
cADPR (5, Fig. 1) had been shown to behave as a compet- 
itive antagonist in inhibiting cADPR-induced Ca2+ release 
[15]. No partial antagonists or partial agonists have yet 
been identified, however. There is, therefore, consider- 
able interest in studying further chemical modifications at 
position 8 of cADPR, in order to explain the structural 
requirements for this antagonism and to design a better 
antagonist. It also seems logical that this antagonism could 
Figure 2 
Schematic diagram to show the Ca*+-release mechanisms in sea 
urchin eggs. In the IP, pathway, phosphatidylinositol 4,5-bisphosphate 
(PIP,) is cleaved by G-protein-coupled phospholipase C (PLC), in 
response to stimulation of a receptor (R), to generate the Ca2+- 
mobilizing second messenger IPs; there is also direct influx of Ca2+ 
from the extracellular medium, and a putative cADPR-mediated second 
messenger pathway. The release of Ca2+ by cADPR is a complex 
process and is not yet well understood. A series of signals from an 
extracellular receptor may result in the cyclization of 8-NAD+ by ADP- 
ribosyl cyclase (C) to give cADPR. This acts in some way on the 
ryanodine receptor (RYR) on an internal Ca2+ store and results in Ca*+ 
release. The action requires calmodulin (CaM), however, and may 
involve the interaction of cADPR binding protein (cADPR-BP) with the 
Ca2+-release channel. There are two distinct ways in which cADPR 
might act: first, as a second messenger analogous to IP,, with 
extracellular stimuli ultimately initiating the cyclization process or, 
second, cADPR might act as a modulator for CICR. In the second 
model, the level of cADPR in the cytoplasm acts to sensitize the 
ryanodine receptor to increases in [Ca*+&. Thus, both cADPR and a 
rise in the internal concentration of cellular Ca2+ are required to trigger 
CICR. The increase in intracellular Ca2+ may come from an influx 
through a plasma membrane channel or from release via the IP, 
mechanism, where IPs acts on its receptor (IPaR) on the endoplasmic 
reticulum (ER). The breakdown of cADPR to ADPR is mediated by the 
enzyme cADPR-hydrolase (H). 
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Figure 3 
The chemo-enzymatic route used to 
synthesize analogues of cADPR, showing the 
structures of 7-deazaadenosine 5’-mono- 
phosphate (2), activated 7-deazaadenosine 
5’-monophosphate (6), 7-deaza NAD+ (3) and 
7-deaza-cADPR (4). 
(PhO),POCI 
c 
(i) 2’,3’-diacetyl NMN 
0) ADP-ribosyl cyclase 
be studied further by exploring the effects of change at 
adjacent positions in the molecule. We have therefore 
investigated the effect of modification at position 7 of 
cADPR. As the first example of this unique modification, 
we have synthesized 7-deaza cADPR (4, Fig. 1) using a 
chemo-enzymatic route. 7-Deaza cADPR is a purine mod- 
ified analogue of cADPR, in which the N7 atom of the 
adenine moiety has been replaced by a carbon atom. Pre- 
liminary modeling studies indicated that this compound 
had a very similar conformation to cADPR itself (data not 
shown). The pharmacological characteristics of this ana- 
logue were evaluated in sea urchin egg homogenates, in a 
comparative study with cADPR. We report here that 
whereas 7-deaza cADPR, like cADPR, can induce Ca2+ 
release from sea urchin egg homogenates, it is less effica- 
cious and represents the first cADPR-based partial 
agonist. These results have implications for the design of 
new cADPR antagonists and for the mechanism of 
cADPR activation of its Ca2+-release machinery. 
Results 
Chemo-enzymatic synthesis of 7-deaza cADPR 
7-Deaza adenosine 5’-monophosphate (2, Fig. 3) was 
prepared using established methods to selectively phos- 
phorylate the 5’-hydroxyl group. In order to minimize 
complications in the subsequent phosphate-coupling step, 
it was necessary to ensure that the product was free of 
contaminating inorganic phosphate. This was achieved by 
adsorption of the nucleotide on to activated charcoal, 
washing with water to remove the inorganic material, and 
elution of the product with aqueous ethanolic ammonia. 
31P NMR spectroscopy showed that the product was free 
from contaminant as there was only a single broad peak 
which sharpened on broad band proton decoupling (data 
not shown). 
The coupling of adenosine 5’-monophosphate analogues 
to nicotinamide mononucleotide (NMN) using dicyclo- 
hexylcarbodiimide [18] and 1-ethyl-3(3-dimethyl-amino- 
propyl)-carbodiimide-HCl [ 151 has previously been used 
to synthesize P-NAD+ analogues. We favoured the more 
chemically flexible method of Michelson, however [19]. 
The 7-deaza cADPR described above was activated by 
forming a mixed anhydride intermediate (6, Fig. 3) using 
diphenyl chlorophosphate (DPPC) in dry dioxane-DMF. 
After evaporation, the residue was dissolved in a mixture 
of dry DMF and dry pyridine and treated with the phos- 
phate monoanion of NMN. The protected 2’,3’-diacetyl 
derivative of NMN had to be used in order to overcome 
the lack of solubility of the unprotected NMN in the reac- 
tion solvent. Displacement of the acidic diphenyl phos- 
phate moiety gave a pyrophosphate product which, after 
deprotection with methanolic ammonia and subsequent 
purification by ion-exchange chromatography, led to 
7-deaza NAD+ (3, Fig. 3). 
ADP-ribosyl cyclase catalyzes the cyclization of P-NAD’ 
to produce cADPR [4] and the ApLyysia enzyme has been 
shown to be quite tolerant with respect to the purine 
base of its substrate [15,16]. Consequently, enzymatic 
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Figure 4 
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Monitoring the cyclization of 7-deaza NAD+ by HPLC. The enzymatic 
cyclization was carried out as described in the Materials and methods 
section: (a) t=O min, 7-deaza NAD+ 100% at 2.19 min; (b) t= 15 min, 
7-deaza cADPR is seen at 4.87 min and the by-product nicotinamide is 
at 1.80 min; (c) t=30 min, the percentage of 7-deaza cADPR had 
increased only nominally so the reaction was quenched immediately. 
cyclization of 7-deaza NAD+ was performed according 
to the protocol previously detailed from this laboratory 
[16]. The formation of the cyclized product, 7-deaza- 
cADPR (4, Fig. I), was monitored by high performance 
liquid chromatography (HPLC; Fig. 4). The retention 
times for 7-deaza NAD+, 7-deaza cADPR and the 
by-product nicotinamide were 2.19 min, 4.87 min and 
l.SOmin, respectively, and the reaction was assumed to be 
complete when the peak assigned to nicotinamide was no 
longer increasing. The cyclization mixture was quenched 
by dilution after 30min, a similar reaction time to that 
required for cADPR itself. 7-Deaza cADPR was easily 
purified from a small amount of unreacted starting material 
and nicotinamide by ion-exchange chromatography. 
The UV spectrum of 7-deaza cADPR has a maximum at 
272nm (compared to 7-deaza adenosine 266nm) whereas 
cADPR has a maximum at 259nm [ZO]. The extinction 
coefficient for 7-deaza cADPR at 272 nm and at pH 7.0 was 
determined by total phosphate analysis of the cyclic 
nucleotide as 8150M-1cm-1 compared to 12200M-1cm-1 
for 7-deaza adenosine. The value of the extinction coeffi- 
cient for 7-deaza cADPR was used to determine the con- 
centrations of 7-deaza cADPR used in the ;est of the 
study. The proton NMR spectrum of the cyclized product 
showed the characteristic shift of the 2’ ribose proton of 
the adenosine moiety: 6=5.4ppm for 7-deaza cADPR, a 
movement from the 4.4ppm for 7-deaza NAD+. The shift 
was analogous to that described for cADPR itself [Zl]. Fast 
atom bombardment mass spectrometry, also confirmed 
cyclization: a mass of 539 for the negative molecular ion 
indicated the loss of nicotinamide. 
The Ca2+-releasing ability of 7-deaza cADPR 
The potency of concentration-dependent Ca2+ release by 
7-deaza cADPR was assayed in sea urchin egg homogenate 
to determine whether this novel compound would be 
effective at releasing Ca2+ from such stores. As shown in 
Figure 5, 7-deaza cADPR was capable of releasing Ca2+ but 
the amount of Ca2+ released was consistently Aess than that 
released by the same concentration of the parent com- 
pound. The half-maximum Ca2+ release (EC,,) induced by 
cADPR and 7-deaza cADPR were 25 + 2 nM, SEM n = 3 and 
90f4nM, SEM n=3, respectively. At maximal concentra- 
tions 7-deaza cADPR was able to release only around 66% 
of the Ca2+ mobilized by a maximal concentration of 
cADPR. Furthermore, this effect was unlikely to be due to 
an enhanced hydrolysis of the analogue by cADPR hydro- 
lases because the half-time for degradation for the 7-deaza 
analogue was considerably longer than for cADPR. This 
indicated that the ‘I-deaza analogue was resistant to hydrol- 
ysis by cADPR hydrolases. (Fig. 6a and inset). 7-Deaza 
cADPR was also tested for its resistance to chemical hydrol- 
ysis. After heating a solution of cAPDR or 7-deaza cADPR 
to 85°C for Zh, the samples were tested for their ability to 
release Caz+. 7-Deaza cADPR was shown not to have lost 
any releasing ability, whereas the sample of cADPR had 
been rendered inactive (Fig. 6b). HPLC analysis of these 
samples (conditions as described in the Materials and 
methods section) also confirmed that 7-deaza cADPR was 
still present in the sample but that all the cADPR had been 
destroyed. In a similar experiment, 7-deaza cADPR and 
cADPR were heated separately in HEPES buffer pH 7.3 
(20mM) at 85°C for 15h. A comparative HPLC study 
showed that whereas all the cADPR had degraded, levels of 
7-deaza ADPR had fallen by only 22% (data not shown). 
The apparent lower intrinsic activity of 7-deaza cADPR 
indicated that it might be a partial agonist in the cADPR 
Caz+-release system. This was tested by examining the 
ability of 7-deaza cADPR to inhibit the maximal Ca*+ mobi- 
lizing properties of cADPR. The maximal Ca2+ released by 
cADPR alone was seen to be decreased by increasing the 
concentration of 7-deaza cADPR (Fig. 7a). Hence, 7-deaza 
cADPR and cADPR can progressively compete for CaZ+- 
release activity, and cADPR can eventually overcome the 
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Figure 5 
The Ca*+-releasing action of cADPR and 
‘I-deaza cADPR on sea urchin egg 
microsomes. Lytechinus pictus egg 
homogenate (2.5%) was prepared and 
challenged with increasing concentrations of 
cyclic compounds as described in the 
Materials and methods section. 
(a) Representative Ca*+-release profiles 
showing the concentration-dependent release 
of Ca*+ as detected by Fluo-3 fluorescence. 
(b) Concentration-response curves of 
cADPR and 7-deaza cADPR (see key on 
figure). The amount of Ca2+ release was 
estimated as described previously [191. The 
concentrations yielding half the maximal 
activity (EC,,) were estimated to 25+ 2 nM 
for cADPR and 90 f 4.4 nM for 7-deaza 
cADPR. 
(a) 
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125nM 
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cADPR 
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94nM 
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inhibition produced by a maximally effective concentration 
of 7-deaza cADPR. Combinations of submaximal concen- 
trations of cADPR and 7-deaza-cADPR appeared to be 
additive, however, (Fig. 7b) so it is unlikely that an inhibi- 
tory metabolite is formed to affect cADPR-induced Ca*+ 
release. These data are consistent with a partial agonist 
action of 7-deaza cADPR. 
Cross desensitization experiments verified that 7-deaza 
cADPR acts at the same Caa+-release channel as cADPR. 
Homogenate that was pre-treated with a supra-maximal 
dose of cADPR (I FM) showed no further Ca2+ release 
when subsequently treated with 7-deaza cADPR (500nM), 
and vice aersa (Fig. 8). In addition, when homogenate was 
treated with B-amino cADPR (ZSOnM), a competitive 
antagonist of cADPR-induced CaZ+ release [15], no further 
Ca2+ release was elicited by subsequent addition of either 
cADPR (500nM) or ‘I-deaza cADPR (500nM). Binding 
studies of [3H]-cADPR to sea urchin egg homogenates 
further confirmed that 7-deaza cADPR and cADPR interact 
with the same binding site. 7-Deaza cADPR was equally as 
effective as cADPR at reducing radio-ligand binding at 
comparable concentrations, indicating similar affinities for 
the same binding site (Fig. 9). 
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Figure 6 
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Stability of 7-deaza cADPR. (a) A comparison 
of hydrolysis of cADPR and 7-deaza cADPR 
in sea urchin egg homogenates. Egg 
homogenates were prepared for fluorimetry as 
described in the Materials and methods 
section. Egg homogenates (2.5%) were 
incubated at 17°C with 2 pM cADPR or 
‘I-deaza cADPR. At the times indicated, 50 PI 
samples were taken and immediately assayed 
for the presence of a Ca2+-mobilizing agonist 
(in 500 (~1 untreated homogenate). The 
starting concentration in the assay cuvette 
was therefore 200 nM for each agonist. The 
amount of Ca2+ released was estimated as 
previously described [20]. Values represent 
means of three experiments f standard error 
(SE). The inset shows the same data, with the 
Ca2+ release recalibrated from the 
concentration-response curves in Figure 5b, 
showing predicted changes in concentrations 
of 7-deaza cADPR and cADPR as a function 
of incubation time. (b) Fluorimetric traces 
showing the action of heat-induced hydrolysis 
on Ca’J+-mobilizing activities of cADPR and 
7-deaza cADPR. Both compounds (200kM) 
were heated in a water-bath to 85-90°C for 
2 h; 5 ~1 samples were taken before and after 
heat treatment and assayed for Cap+-releasing 
ability in 2.5O/o egg homogenate. Traces are 
representative of three determinations. 
Whereas the Ca2+-mobilizing activity of 
cADPR (2 ~.LM in the assay cuvette) was 
completely abolished following heat treatment, 
the activity of 7-deaza cADPR (similarly 2 ~.LM 
in the assay cuvette) remained unaffected. 
Discussion 
Recently, there has been intense interest in the involve- 
ment of cADPR in the mechanism of CaZ+ release within 
cells. The realization that cADPR-induced Caa+ mobiliza- 
tion operates in a wide number of different tissue types 
and cell lines [Z], including T cells [23,24] and cardiac 
myocytes [25], has added considerable impetus to this 
field. Clearly, in order to improve our understanding of 
this system and elucidate the nature of the receptor for 
cADPR, structure-activity studies are urgently required. 
Until now, however, little work using structurally modi- 
fied analogues of cADPR, other than modifications at 
position 8, has been reported. 
The demonstration of the loose substrate specificity of 
Aplysia cyclase, the cyclizing enzyme, has reduced the 
problem of synthesizing cADPR analogues broadly to one 
of synthesizing the corresponding P-NAD+ analogues - a 
much more straightforward chemical task. In fact, it is rea- 
sonable to suggest that the only major limiting factor 
involves modification to the pyrimidine ring. For example, 
the use of nicotinamide guanine dinucleotide and nicoti- 
namide hypoxanthine dinucleotide leads to N7 ribosyla- 
tion, not Nl ribosylation (our unpublished observations 
and see [26]). Conversely, all modifications to the imida- 
zole ring and the adenosine ribose that we have made 
have been accepted by the enzyme. 
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Figure 7 
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Action of 7-deaza cADPR as a partial agonist. Egg homogenates were 
prepared for fluorimetry as described in the Materials and methods 
section. (a) The maximal amount of Ca*+ released from sea urchin egg 
microsomes by 500 nM cADPR was decreased when it was added at 
the same time as increasing concentrations of ‘I-deaza cADPR. 
(b) The effect of co-addition of submaximal concentrations of the two 
agonists. The values represent mean of triplicates *SE. 
The overall chemical strategy is, therefore, to prepare, by 
synthesis or otherwise, a structurally modified adenosine 
nucleoside, and then to phosphorylate this compound 
Figure 8 
directly and regioselectively using P(V) chemistry. Subse- 
quent coupling of the product to NMN leads to the corre- 
sponding P-NAD+ analogue and enzymatic cyclization of 
this analogue leads in turn to an analogue of cADPR. The 
recent advent of the poorly hydrolyzable analogue of 
cADPR, cArisDPR [ 171, using this chemo-enzymatic 
strategy is a powerful demonstration of the immediate 
utility of the method. Use of this analogue in place of 
cADPR may highlight the presence of cADPR in tissues, 
which has not yet been detected, perhaps because of its 
rapid hydrolysis. 
A starting point for the systematic study of the structure- 
activity relationships and the design of new antagonists 
is clearly the modification of position 8 of cADPR, 
because g-amino cADPR is already documented as a com- 
petitive antagonist [15,20]. As groups at position 8 have 
such a dramatic influence on Ca2+-mobilizing activity the 
adjacent position 7 is also an obvious target for chemical 
modification. We therefore decided to delete the N7 
atom of the imidazole ring. Modeling of this compound 
showed it to be of a similar conformation to cADPR. 
When a comparison of the pharmacology of I-l-deaza 
cADPR and cADPR was made, however, our results 
demonstrated that 7-deaza cADPR had a Ca2+-release 
profile consistent with it being a partial agonist. The 
release of Ca2+ by 7-deaza cADPR indicated that the N7 
atom is not essential for receptor binding and activation. 
Nevertheless, the absence of the N7 atom clearly inter- 
fered with the Ca2+-release machinery, such that a sub- 
maximal release was observed. It is difficult at present to 
rationalize this observation in molecular terms, but the 
observation that cADPR is a full agonist and 7-deaza 
cADPR is a partial agonist may potentially reflect a 
requirement for hydrogen bonding at position N7 of the 
7-Deaza cADPR acts on cADPR-sensitive 
Ca*+-release channels. Egg homogenates 
were prepared for fluorimetry as described 
in the Materials and methods section. 
Representative Ca*+-release profiles for both 
(a) 7-deaza cADPR and (b) cADPR show 
that both compounds release Ca2+ via the 
same channels in sea urchin egg 
homogenate (2.5%). Pretreatment of the 
homogenate with the cADPR antagonist 
8-amino cADPR (250 nM) completely 
inhibited subsequent release by 500 nM 
7-deaza cADPR and substantially decreased 
that induced by 500 nM cADPR. Receptors 
desensitized by pretreatment with a 
supra-maximal concentration of cADPR 
inhibited further Ca*+ release by a 
subsequent addition of 500 nM 7-deaza 
cADPR, and vice versa. 
+ 8NH2 cADPR (250 nM) 
Desensitized with cADPR (1 /.LM) 
7-deaza cADPR (500nM) cADPR (500 nM) 
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Figure 9 
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Action of ‘I-deaza cADPR on [3H]-cADPR binding in sea urchin egg 
homogenates. PHI-cADPR binding was determined in sea urchin 
homogenates as described in the Materials and methods section. 
Specific cADPR binding was demonstrated by the amount of 
radiolabeled cADPR displaced by a maximal concentration of cADPR 
(1 FM); this was approximately 67% of total bound label. The same 
concentration of 7-deaza cADPR (1 PM) was equally effective at 
reducing radioligand binding. This result confirms that 7-deaza 
cADPR and cADPR interact with the same binding site. When 
radiolabeled cADPR (20nM) was incubated with an equimolar 
concentration of 7-deaza cADPR, this resulted in approximately 50% 
displacement of specifically bound radioligand, suggesting that the 
binding affinities may be similar. Values represent mean f SE of 
triplicate experiments. 
adenine ring. The 7-deaza compound might be expected 
to present itself to the receptor in a similar way to 
cADPR, albeit now lacking one hydrogen-bond interac- 
tion and potentially interfering sterically with a putative 
hydrogen-bond donor. ‘I-Deaza cADPR is clearly never- 
theless able to mimic cADPR sufficiently to induce sub- 
stantial Ca*+ release. In the case of the antagonist S-amino 
cADPR, however, the amino group might cause binding 
to the receptor in a way different to that of either 7-deaza 
cADPR or cADPR itself, thus shearing the molecule into 
an unfavourable conformation for the stimulation of ion- 
channel opening. These considerations must operate 
within the limitations of steric constraints at position 8 
because it is known that bulky and hydrophobic sub- 
stituents at position 8 lead to reduced and eventual loss of 
antagonist activity in sea urchin egg homogenate (our 
unpublished observations). 
These results are also the first to demonstrate that resis- 
tance to hydrolytic stability in a cADPR analogue may also 
be engendered by a modification at position 7. Clearly, 
7-deaza cADPR is not degraded as rapidly as is cADPR 
(Fig. 6) so it complements cArisDPR [17] in biological 
applications requiring metabolic stability. 
Further work in this area is necessary before we under- 
stand the structural requirement for effective antagonism 
and in order to investigate the interplay of substituents at 
both position 7 and position 8. What is clear, however, is 
that this region of the imidazole ring is important in stim- 
ulating the CaZ+-release machinery. In addition, such 
modification, perhaps in conjunction with that at position 
8, should produce compounds of interesting biological 
activity. Thus, the results presented here further support 
the use and viability of the chemo-enzymatic approach 
for the production of pharmacologically important ana- 
logues of cADPR. They also provide a key new lead in 
the design of compounds to modulate the activity of 
cADPR. In addition, the data help to define how cADPR 
binding leads to the activation and opening of its target 
Caz+-release channel. 
Significance 
cADPR is a novel candidate second messenger whose 
properties are leading us to re-evaluate our understand- 
ing of cellular Caz+ signaling. It has been shown to be 
active in a wide range of cell types in which its action is 
clearly of importance. A full understanding of its mecha- 
nism of action and interplay with other Ca2+-release 
pathways is, therefore, of great pharmacological impor- 
tance. At present there are very few molecular probes 
with which the action of cADPR can be investigated. By 
developing and exploiting a chemo-enzymatic synthetic 
approach, we have been able to synthesize analogues of 
cADPR from their parent nucleosides, which will allow 
a range of modified structures to be created. The only 
limiting factor is the substrate specificity of the cyclizing 
enzyme. Making small but significant changes in the 
structure of each new analogue can often result in dra- 
matic differences in biological activity and so lead to the 
production of useful pharmacological tools. 
In this paper, we describe the synthesis and evaluation 
of the first partial agonist of the cADPR Ca2+-release 
mechanism. This compound is of significance by virtue 
of the demonstration that cADPR analogues of lower 
efficacy and with hydrolytic resistance can be obtained 
by modification at position 7 of the adenine ring. This 
points to a highly sensitive area around positions 7 and 8 
of the imidazole ring. 7-Deaza cADPR is a key new 
lead compound; by further investigating the interplay of 
positions 7 and 8 together, we should be able to synthe- 
size compounds with interesting biological activity and 
enhanced antagonist potential. Such tools will help us to 
understand how cADPR binding leads to Ca2+ release 
in this novel signaling pathway. 
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Materials and methods 
Materials 
7-Deaza adenosine (Tubercidin), nicotinamide mononucleotide 
(NMN), and 2-[4-(2-hydroxyethyl) piperazin-1 -yl] ethanesulphonic acid 
(HEPES) were purchased from Sigma (London). ADP-ribosyl cyclase 
was isolated from Aplysia califomica as described 1271 and was used 
crude. cADPR and 8-amino cADPR were synthesized as described 
[18] and were purified by Q-Sepharose low-pressure ion-exchange 
chromatography and isolated as their triethylammonium salts. Fluo-3 
dye was purchased from Calbiochem and fluorescence was monitored 
using a Perkin-Elmer LS-SOB fluorimeter. NMR spectra were recorded 
on a Jeol FX-900, GX-270 or GX-400 spectrometer as indicated and 
chemical shifts were measured in parts per million (ppm) relative to the 
residual protonated solvent. 31 P spectra are also quoted in ppm relative 
to external 85% HsPO,; chemical shifts are positive when downfield 
from this reference. J values are given in Hz and the following abbrevia- 
tions are used: s, singlet; d, doublet; t, triplet; m, multiplet. Mass 
spectra were recorded at the University of Bath Mass Spectrometry 
Service using positive and negative fast atom bombardment with 
m-nitrobenzyl alcohol as the matrix; the electrospray mass spectrum 
was recorded at the SERC Mass Spectra Service, University of 
Swansea. HPLC was performed on a Shimadzu LC-GA chromatograph 
with UV detection at 259nm and using a 1 Ot~rn Partisil SAX anion 
exchange column isocratically eluted with 0.05 M KH,PO,/B% MeOH 
buffer. Ion-exchange chromatography was performed using a LKB 
Gradifrac system with the column packed with Q-Sepharose Fast Flow 
resin (Pharmacia) in the bicarbonate form. Gradient elution was per- 
formed using an ion-exchange buffer system of triethylammonium bicar- 
bonate (TEAB) at pH 7.8. All other chemicals were purchased from 
Aldrich Chemical Company and solvents were distilled and dried using 
standard techniques. 
Preparation of 7-deaza adenosine 5’-monophosphate (2). 
7-Deaza adenosine was selectively phosphorylated at the 5’-hydroxyl 
using methods based on those described by Yoshikawa et al. [28] for 
the phosphorylation of nucleosides. A mixture of dry 7-deaza adenosine 
(82mg, 308p,mol) and triethyl phosphate (1 ml) was heated at 50°C 
for 15 min. The suspension was cooled to 0% and phosphorus oxy- 
chloride (50 t.d, 535 p,mol) was added drop-wise. A clear solution was 
seen after 5 min and this was stirred at 4% for 18 h. Iced water (10 ml) 
was added and the mixture was stirred for a further 2 h. The product 
was purified by ion-exchange chromatography using a gradient of 0 to 
300 mM TEAB over 720 ml and the nucleotide eluted between 190 mM 
and 220mM. Appropriate fractions were pooled and evaporated in 
vacua and excess TEAB was coevaporated with MeOH. 
The nucleotide was further purified from contaminating inorganic phos- 
phate by adsorption on to activated charcoal (291 by dissolving the 
product in water and stirring with the charcoal (1 g) for 15 min. The char- 
coal was filtered off, washed with water and the product was desorbed 
by elution with 25:24:1 (v\v\v) ethanol-water-concentrated ammonia 
(500ml). The eluate was evaporated to dryness to give the title 
compound (2) as the ammonium salt in 48% yield as calculated by UV 
analysis. NMR: 6, (270MHz, D,O) 3.94 (2H, m, H5’), 4.19 (1 H, dt, 
J=3.1, 5.2Hz, H4’), 4.30 (lH, dd, J=3.1, 5.0Hz, H3’), 4.49 (lH, dd, 
J=5.0, 6.7Hz, H2’), 6.14 (lH, d,J=6.7Hz, Hl’), 6.72 (lH, d, J=4.0Hz, 
H7), 7.54 (lH, d, J=4.0Hz, H8), 8.08 (lH, s, H2). 6, (161.7MHz, D,O) 
0.02ppm (td, J,,=2.4, 4.9Hz). 6, (100.4MHz, D,O) 67.3, 73.5, 77.1, 
86.8, 89.2, 101.7, 105.5, 127.2, 145.3, 150.4, 153.9. UV: h,,=266nm, 
E= 12.2x 1 O3 M-l cm-r 1301. HPLC single peak at 1.98 min (compared to 
adenosine 5’-monophosphate 2.15min). 
Preparation of 2<3’-diacetyl NMN. 
2’,3’-Diacetyl NMN was prepared from NMN essentially as described 
[31]. A solution of NMN, free acid, (15mg, 50 kmol) in Hz0 (0.1 ml) was 
added drop-wise to a rapidly stirred solution of acetic anhydride 
(0.78ml) in dry pyridine (1.2ml). The reaction mixture was stirred at room 
temperature for 2 h and then overnight at 4°C. The solvent was removed 
in vacua, keeping the bath temperature at 30°C, and the residue was 
stirred with aqueous pyridine (1 ml) for 0.5 h to destroy any mixed anhy 
dride and any excess of acetic anhydride. After removal of the solvent, 
the resulting residue was dissolved in MeOH (0.5ml) and tri-n-octy 
lamine (22 $, 50 p,mol) was added. The mixture was stirred for 0.5 h and 
the MeOH was evaporated. The residue was dried three times by 
coevaporation of any excess water with dry dimethyl formamide (DMF) 
and the resulting crude product was used directly in the next step. 
Preparation of 7-deaza NAD+ (3) 
Coupling of the nucleotides was accomplished essentially using the 
Michelson procedure [191. ‘I-Deaza adenosine 5’-monophosphate, free 
acid, (2, Fig. 3; 25mg, 72 pmol) was dissolved in anhydrous MeOH 
(0.5 ml). To this was added one equivalent of tri-n-octylamine (32 111) and 
the mixture was stirred until a clear solution was seen, (-0.5 h). The 
solvent was evaporated and the resulting mono-tri-n-octylammonium salt 
was dried by evaporation of three volumes of dry DMF (1 ml). The 
residue was dissolved in a mixture of dry DMF (0.3 ml) and dry dioxane 
(0.5 ml) and diphenyl chlorophosphate (DPPC, 20 PI, 100 pmol) was 
added, followed by tri-n-butylamine (20 ~1, 75 pmol) An homogeneous 
solution formed after a few minutes and this was further stirred at room 
temperature for 2 h. After this time a 31P NMR spectrum (36.2MHz, 
D,O in a 1Omm outer tube) showed the formation of the activated 
nucleotide intermediate (6, Fig. 3) to be complete, with no peak remain- 
ing at approximately Oppm corresponding to 7-deaza adenosine 
5’ monophosphate. The solvent was evaporated in vacua and the 
residue was shaken with cold, dry ether (to remove any unreacted 
diphenyl chlorophosphate) to give a white solid. The majority of the 
ether was decanted and any residual ether was removed by evaporation. 
Activated 7-deaza adenosine 5’-monophosphate (6, Fig. 3) was 
dissolved in dry DMF (0.2ml). 2’,3’-Diacetyl NMN, used directly from the 
previous step, was also dissolved in DMF (0.3ml). The solution was 
added to the activated nucleotide followed immediately by dry pyridine 
(0.5 ml) and the reaction was stirred at room temperature for 18 h. After 
this time, the solvent was evaporated and the product was deacetylated 
in situ by dissolving the residue in ice-cold methanolic ammonia (1 :l ratio 
of MeOH with 35% ammonia solution with a total volume of 1 ml) and 
stirring for 6 h at 4%. The solvent was removed in vacua and the residue 
was purified by ion-exchange chromatography using a gradient elution of 
0 to 250mM TEAB over 720ml. The fractions containing the product, 
which eluted between 120 mM and 140 mM, were pooled, evaporated in 
vacua and excess TEAB was coevaporated with MeOH. The title com- 
pound (3, Fig. 3) was obtained as the triethylammonium salt in 38% yield 
over the two steps, as quantified by UV measurements. NMR: 6, 
(270MHz, D,O) 1.24 (9H, t, J=7.3Hz, N(CH,CH,),), 3.17 (6H, q, 
J=7.3Hz, N(CH,CH,),), 4.0-4.1 (4H, m, 2H,5’, 2H,5’), 4.19 (1 H, m, 
H,3’), 4.25 (1 H, m, H,3’), 4.29 (lH, m, H,4’), 4.38 (lH, dt, J=5.3, 
4.9Hz, H,2’), 4.42 (lH,m,H,2’),4.46 (lH, t, J=5.7Hz, H,4’), 6.11 (lH, 
d, J=5.3Hz, H/,1’), 6.16 (lH, d, J=6.4Hz, H,l’), 6.65 (lH,d, J=3.6Hz, 
H,7), 7.53 (lH,d,J=3.6Hz, H,8), 8.09 (lH, s, H,2), 8.16 (lH, dd, 
J=8.1, 6.4Hz, H,3), 8.78 (lH, d, J=8.1Hz, H,4), 9.15 (lH, d, J=6.4Hz, 
H,6), 9.33 (lH, s, H,2). 6, (161.7MHz, D,O) -11.8, -11.4ppm (2d, 
J,,=21.8Hz). F, (100.4MHz, D,O) 9.1, 47.5, 65.8, 66.5, 71.3, 71.6, 
75, 78.5, 84.5, 87.2, 87.9, 100.9, 103, 103.4, 124.6, 129.5, 134.4, 
140.8, 143.3, 146.6, 149.1, 152.4, 155, 166.2. UV: X,,=266nm, 
E= 12.7 x 1 O3 M-‘cm-’ 1321. HPLC single peak at 2.19 min (compared to 
@NAD+ 2.48min). m/z (electrospray) 663 (M+), 662 (M+-l), 661 
(M+-2), 540 (M+-nicotinamide), 539 (M+-nicotinamide-1). 
Synthesis of 7-deaza cADPR (4) 
‘I-Deaza NAD+ (3, Fig. 3) was cyclized enzymatically using similar 
methods to those previously detailed [16]. A final volume of 2.5 ml of 
a 1.5mM solution of 7-deaza NAD+ in 25 mM HEPES buffer at pH 
6.8 was incubated with 10 t.~l of crude Aplysia ADP-ribosyl cyclase at 
room temperature. The reaction was monitored by HPLC (Fig. 4) and 
was quenched by a 20-fold dilution of the reaction mixture with water 
when the peak attributable to the product was no longer seen to be 
increasing. The desired product was isolated from a small amount of 
60 Chemistry & Biology 1997, Vol 4 No 1 
unreacted starting material and the by-product nicotinamide using ion- 
exchange chromatography eluting with 0 to 250mM TEAB. The 
product, which eluted between 90 and 1 10 mM TEAB, was evaporated 
to dryness in vacua keeping the water-bath temperature below 30%. 
Excess TEAB was removed by evaporation with MeOH and the title 
compound (4) was isolated in 57% yield by UV as the glassy triethyl- 
ammonium salt and stored at -70%. 
The product was quantified by total phosphate analysis using a modifica- 
tion of the Briggs test [33]. Three accurately known quantities of the 
sample were diluted in water (400 ~1) and heated to dryness. The phos- 
phate anhydride and resulting esters were hydrolyzed by addition of a few 
drops of cont. H,SO, and by further heating at 175°C for 1.5 h. The 
samples were then cooled and the following solutions added: H,O 
(200 ~1); ammonium molybdate (400 ~1; 12.5%w/v in water with 8 ml of 
cone H,SO,); hydroquinone (200 ~1; 0.5% w/v in water with one drop of 
cone H,SO,) and sodium sulphite (200 ~1; 20% w/v in water). Each solu- 
tion was boiled vigorously for 10 s, transferred to a volumetric flask and 
made up to 5 ml with water. Each sample was repeated in triplicate and 
the UV absorbance was recorded at 340 nm. The amount of phosphate in 
each sample was calculated from a standard curve constructed using 
known amounts of KH,PO, treated exactly as above and prepared imme- 
diately before use. This allowed the extinction coefficient to be calculated 
for the novel product. NMR 6, (400 MHz, D,O) 1.24 (3H, t, J= 7.3H.z, 
N(CH,CH,),), 3.17 (2H, q, J=7.3Hz, N(CH,CH,),), 3.9-4.45 (6H, m, 
2H,5’, 2H,5’, H,4’, H,3’), 5.34 (1 H, dd, J=5.6, 6.4 Hz, H,2’), 5.75 (1 H, 
d, J=6.4Hz, H,l’), 6.01 (lH, d, J=4.0Hz, H,l’), 6.71 (lH, d, J=3.7Hz, 
H,7), 7.31 (lH, d, /=3.7Hz, H,8), 8.75 (lH, s, H,2); other protons are 
obscured by the water peak at 4.8ppm. 6, (161.7 MHz, D,O) -12.7, 
-13.4ppm (2d, J,=14.4Hz). UV: A,,= 272nm, ~=8.15xlO~M-~cm-‘. 
HPLC: single peak at 4.87min (compared to cADPR 4.20min). m/z 
(FAB+) 541 (M+H)+, (FAB-) 539 (M-H)-. 
Calcium-release measurements 
Lytechinus pictus egg homogenate (2.5% v/v), prepared as previously 
described [201, was incubated at 17°C in intracellular-like medium (IM) 
containing an adenosine 5’-triphosphate-regenerating system, mito- 
chondrial inhibitors and Flue-3 (3 FM), and extra-microsomal Ca*+ was 
measured by monitoring Flue-3 fluorescence (excitation 490nm and 
emission 535 nm). Homogenate (0.5 ml) was placed in a cuvette and 
5~1 additions of test compound (dissolved in IM with 10pM EGTA) 
were made. Estimates of the amount of Ca*+ released were based on 
calibrations with known amounts of Ca*+ added to the assay 
homogenate, as described previously [20]. 
Determination of PHI-cADPR binding 
[3H]-cADPR binding was determined in sea urchin homogenates as 
described by Genazzani et a/. [34]. In brief, homogenates were diluted 
in Glu-IM containing 1 mM EGTA to a concentration of 1 mgml-’ 
protein (-3.5%) and incubated with 20nM L3H]-cADPR for 10min at 
4°C. Non-specific binding was assessed with 1 PM cADPR. Binding 
was terminated by filtration (fiberglass GF/B filters) under vacuum and 
filters were rapidly washed twice with ice-cold Glu-IM. Filters were 
dissolved in 14 ml scintillation fluid and radioactivity was determined by 
liquid scintillation counting. 
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